TITLE

PHARMACEUTICALS TO EXPERIENCE WIDE CHANGES

PUB. DATE
April 2011
SOURCE
Worldwide Biotech;Apr2011, Vol. 23 Issue 4, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports positive changes in the global pharmaceutical market as of April 2011. According to financial online portal World Street Fundamentals, Novavax Inc. closed a 97 million U.S. dollar contract with the U.S. Department of Health and Human Services (HHS) for its technology platform. Market projections for the cancer test kit developed by Radient Pharmaceuticals can reach as high as 1.45 billion U.S dollars yearly. Favorable market environments are also projected for the Asia-Pacific region.
ACCESSION #
59633533

 

Related Articles

  • Novavax, VaxInnate Get Welcome Shot in the Arm. Serebrov, Mari // BioWorld Today;3/2/2011, Vol. 22 Issue 41, p1 

    The article reports on the contracts awarded by the U.S. Department of Health and Human Services (HHS) to Novavax Inc. and VaxInnate Inc. Under the contract, Novavax will receive 97 million U.S. dollars over the first three years to bring its seasonal influenza recombinant virus-like particle...

  • Chronic problem.  // Echo Magazine;5/4/2006, Vol. 17 Issue 17, p43 

    Reports on the rejection of the use of marijuana for medical purposes by the U.S. Food and Drug Administration (FDA) and other agencies with the Health and Human Services Department. Inconsistency of legislation that allow the use of marijuana with the efforts to ensure that medications undergo...

  • Lilly agrees to compliance checks for Zyprexa. M. A. // Medical Marketing & Media;Feb2009, Vol. 44 Issue 2, p9 

    The article reports on the Corporate Integrity Agreement (CIA) of Eli Lilly and Co. and the Health and Human Services (HHS) Office of Inspector General in the U.S. The agreement is accordingly entered as the compliance of the company for the off-label marketing of Zyprexa. Around $1.145 billion...

  • BARDA AWARDS UP TO $143 MIL FOR DEVELOPMENT OF ANTHRAX DRUG.  // Biotech Financial Reports;Jan2010, Vol. 17 Issue 1, p8 

    The article reports on the contract awarded to Elusys Therapeutics Inc. by the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of anthrax drug. It states that 16.8 million dollars is valued during the first...

  • RxBio Inc, Biopharmaceutical Affiliate of Univ of Tennessee Health Science Center, Receives $15 Mln Federal Contract from Biomedical Advanced R&D Authority.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p566 

    The article reports on the 15 million-dollar contract granted to biopharmaceutical company RxBio Inc. of the University of Tennessee Health Science Center (UTHSC) in Memphis, Tennessee by the U.S. Department of Health & Human Services' (DHHS) Biomedical Advanced Research & Development Authority...

  • Merck vows marketing reforms in CIA. Dickinson, James G. // Medical Marketing & Media;Apr2008, Vol. 43 Issue 4, p12 

    The article reports on Merck & Co. Inc.'s vow to maintain corporate policies and guidance documents on marketing in the U.S. Merck made the agreement with the Department of Health and Human Services to resolve corporate issues involving alleged improper marketing practices. The company's...

  • BARDA funds development of new way to treat illness from acute radiation.  // Biomedical Market Newsletter;12/20/2010, p154 

    The article reports that the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded 153 million dollar contract to Cellerant Therapeutics Inc. to develop a new way to treat an illness caused by exposure to high levels of ionizing...

  • Some Thoughts About Scientific Bias. Gonzalez, Nicholas J. // Townsend Letter;Jul2010, Issue 324, p40 

    The article discusses the scientific bias shown by the U.S. Office of Human Research Protections (OHRP) against a study launched by scientists from Columbia University, the National Center for Complementary and Alternative Medicine (NCCAM) and the National Cancer Institute. The project aims to...

  • Regulatory New Drug Review: Solutions for Study Data Exchange Standards; Notice of Meeting; Request for Comments; Correction. Kux, Leslie // Federal Register (National Archives & Records Service, Office of;9/17/2012, Vol. 77 Issue 180, p57055 

    The article offers information on a notice issued by the U.S. Department of Health and Human services regarding the correction of a document by the U.S. Food and Drug Administration (FDA) related to Study Data Exchange Standards for new drug regulation.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics